US Stem Cell Stock

US Stem Cell Current Assets

The Current Assets of US Stem Cell (USRM) as of Aug 12, 2026 is 68,000.00 USD. In the previous year, Current Assets was 51,000.00 USD — a change of 33.33% (higher).

Current Assets

68,000.00USD

YoY

33.33%

Last updated:

Current Assets of US Stem Cell is 2026 68,000.00 USD. Current Assets of US Stem Cell was 2025 51,000.00 USD. It decreases by 33.33% higher compared to the previous year.
Access this data via the Eulerpool API

US Stem Cell Stock analysis

What does US Stem Cell do? US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry. US Stem Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about US Stem Cell stock

Current Assets of US Stem Cell is 68,000.00 USD in 2026.

Current Assets of US Stem Cell changed from 51,000.00 USD to 68,000.00 USD, representing a 33.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets US Stem Cell since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's US Stem Cell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — US Stem Cell

All Key Metrics — US Stem Cell